Professor
Children's Foundation Research Institute at LeBonheur Children's Hospital and UTHSC Dpt of Pediatrics
Dr DeVincenzo is a practicing Pediatric Infectious Diseases specialist at Le Bonheur Children’s Hospital, and Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research has focused on understanding the pathogenesis of respiratory syncytial virus (RSV) and developing therapeutic and prevention strategies against this virus. He is the author of over 250 original published abstracts and papers on this subject. Dr. DeVincenzo has been developing RSV antivirals and vaccines using a variety of approaches; from conception to proof of concept clinical trials through academic, foundation, and industry pathways. He and colleagues have now demonstrated the first evidence that treating an established RSV infection in humans can lower the viral load and result in reduced disease. He has recently extended similar proofs of human antiviral RSV-therapeutic efficacy for four other novel antiviral compounds and is currently progressing international RSV antiviral programs into pediatric and adult populations.
Dr. DeVincenzo graduated from Stanford, and then Vanderbilt Medical School. Completing residency at U.C.L.A, he then studied tropical medicine at Walter Reed and practiced medicine in Central Africa before starting Pediatric Infectious Diseases training at Boston Children’s Hospital and Harvard Medical School. During this time, he worked with his mentor, George Siber, in developing passive antibody approaches for RSV treatment and prevention. Dr. DeVincenzo has conducted numerous clinical and translational trials refining the pathogenesis of RSV and defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immune suppressed. He and his laboratory have received numerous honors including induction into Alpha Omega Alpha National Medical Honor Society (2009), the Healthcare Heroes Award for innovation (2008), and the best advance in Therapy and Prevention of a Microbial Disease (ICAAC 2007). Dr. DeVincenzo is currently also the clinical director of the Methodist/Le Bonheur Molecular Diagnostics Laboratory and is involved in award winning clinical teaching of med students, residents, and fellows.
Disclosure: ADMA Biologics (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Alnylam (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Other Financial or Material Support, Research Grant or Support, Stock options; Alveo (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant; Ark Bio (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Other Financial or Material Support, Research Grant or Support, Scientific Research Study Investigator, Stock Options; Enanta (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant; Gilead (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; hVivo (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Janssen (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; MedImmune/AstraZeneca (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator, Speakers' bureau; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant; Meridian (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Other Financial or Material Support, Research Grant or Support, Scientific Research Study Investigator, Virus for experimental human infection; Pfizer (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Pulmocide (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Regeneron (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Sanofi Pasteur (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Speakers' bureau; Teva (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Grant/Research Support, Research Grant or Support, Scientific Research Study Investigator; Vir Bio (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant
Thursday, October 22, 2020
3:45pm – 5:00pm EDT
